Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYE201/MK-8748 versus aflibercept in neovascular age-related macular degeneration
2025-524575-22-00Phase 3Authorised
- Sponsor
- EyeBio
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of tiespectus in exudative macular degeneration (3 arms), sponsored by EyeBio. Primary endpoint: Mean change in BCVA (ETDRS letters) from baseline to Year 1. Planned start Jun 2026; status: authorised.
02
Drugs
tiespectus
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2025-524575-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524575-22-00.